Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 150 of 162 entries
View as:

Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04004221 Org: User:
Start: 06/16/17 End: 03/11/21 Due: 03/11/22

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04532294 Org: User:
Start: 09/08/20 End: 02/13/21 Due: 02/13/22

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03430843 Org: User:
Start: 01/26/18 End: 12/28/22 Due: 12/28/23

Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06906809 Org: User:
Start: 04/03/25 End: 06/16/25 Due: 06/16/26

A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)

Phase: N/A Priority: Normal
NCT ID: NCT03053440 Org: User:
Start: 01/25/17 End: 06/21/22 Due: 06/21/23

Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03379259 Org: User:
Start: 11/27/17 End: 09/08/20 Due: 09/08/21

Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants

Phase: N/A Priority: Normal
NCT ID: NCT04382586 Org: User:
Start: 07/06/20 End: 02/01/21 Due: 02/01/22

Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03206918 Org: User:
Start: 03/09/17 End: 09/10/20 Due: 09/10/21

Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04883957 Org: User:
Start: 07/05/21 End: 04/30/26 Due: 04/30/27

Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05767398 Org: User:
Start: 03/07/23 End: 04/28/23 Due: 04/28/24

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03783442 Org: User:
Start: 12/11/18 End: 08/22/24 Due: 08/22/25

Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03777657 Org: User:
Start: 12/13/18 End: 08/27/24 Due: 08/27/25

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04215978 Org: User:
Start: 01/30/20 End: 01/24/25 Due: 01/24/26

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06756932 Org: User:
Start: 02/04/25 End: 06/30/27 Due: 06/30/28

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT05006716 Org: User:
Start: 09/13/21 End: 12/31/28 Due: 12/31/29

Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03744468 Org: User:
Start: 11/13/18 End: 02/06/25 Due: 02/06/26

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04746924 Org: User:
Start: 06/08/21 End: 03/31/26 Due: 03/31/27

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT05828589 Org: User:
Start: 06/20/23 End: 04/30/27 Due: 04/30/28

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Phase: N/A Priority: Normal
NCT ID: NCT04116437 Org: User:
Start: 10/15/19 End: 10/31/25 Due: 10/31/26

A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy

Phase: N/A Priority: Normal
NCT ID: NCT05707377 Org: User:
Start: 04/17/23 End: 04/30/28 Due: 04/30/29

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05100862 Org: User:
Start: 03/10/22 End: 06/30/30 Due: 06/30/31

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Phase: N/A Priority: Normal
NCT ID: NCT06943872 Org: User:
Start: 06/11/25 End: 12/31/32 Due: 12/31/33

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Phase: N/A Priority: Normal
NCT ID: NCT03206970 Org: User:
Start: 03/02/17 End: 09/08/20 Due: 09/08/21

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04952597 Org: User:
Start: 07/15/21 End: 07/26/23 Due: 07/26/24

Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function

Phase: N/A Priority: Normal
NCT ID: NCT03465059 Org: User:
Start: 05/30/18 End: 10/19/18 Due: 10/19/19